Sachin H. Bhagchandani

Sachin H. Bhagchandani

Auto-generated profile, based on publicly available information

Sachin H. Bhagchandani

Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
SBSachin Bhagchandani
Sachin Bhagchandani
JJJeremiah A. Johnson
Jeremiah A. Johnson
DIDarrell J. Irvine
Darrell J. Irvine
Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin cancer treatments. Nevertheless, these innate immune system-activating drugs have potentially much broader therapeutic utility; they have been pursued as antitumor immunomodulatory agents and more recently as candidate vaccine adjuvants for cancer and infectious disease. The broad expression profiles of TLR7/8, poor pharmacokinetic properties of IMDs, and toxicities associated with systemic administration, however, are formidable barriers to successful clinical translation. Herein, we review IMD formulations that have advanced to the clinic and discuss issues related to biodistribution and toxicity that have hampered the further development of these compounds. Recent strategies aimed at enhancing safety and efficacy, particularly through the use of bioconjugates and nanoparticle formulations that alter pharmacokinetics, biodistribution, and cellular targeting, are described. Finally, key aspects of the biology of TLR7 signaling, such as TLR7 tolerance, that may need to be considered in the development of new IMD therapeutics are discussed.

21 April 2023 in Science Advances
Verified
Journal Article
Open access
SBSachin H. Bhagchandani
Sachin H. Bhagchandani
FVFarrukh Vohidov
Farrukh Vohidov
LMLauren E. Milling
Lauren E. Milling
ETEvelyn Yuzhou Tong
Evelyn Yuzhou Tong
CBChristopher M. Brown
Christopher M. Brown
JJJeremiah A. Johnson
Jeremiah A. Johnson
Imidazoquinolines (IMDs), such as resiquimod (R848), are of great interest as potential cancer immunotherapies because of their ability to activate Toll-like receptor 7 (TLR7) and/or TLR8 on innate immune cells. Nevertheless, intravenous administration of IMDs causes severe immune-related toxicities, and attempts to improve their tissue-selective exposure while minimizing acute systemic inflammation have proven difficult. Here, using a library of R848 “bottlebrush prodrugs” (BPDs) that differ only by their R848 release kinetics, we explore how the timing of R848 exposure affects immune stimulation in vitro and in vivo. These studies led to the discovery of R848-BPDs that exhibit optimal activation kinetics to achieve potent stimulation of myeloid cells in tumors and substantial reductions in tumor growth following systemic administration in mouse syngeneic tumor models without any observable systemic toxicity. These results suggest that release kinetics can be tuned at the molecular level to provide safe yet effective systemically administered immunostimulant prodrugs for next-generation cancer immunotherapies.

19 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
KSKeyla Sá
Keyla Sá
JSJulio Silva
Julio Silva
RBRafael Bayarri-Olmos
Rafael Bayarri-Olmos
CBChristopher A. Baker
Christopher A. Baker
ZLZhenni Lu
Zhenni Lu
AIAkiko Iwasaki
Akiko Iwasaki
Summary: Acute SARS-CoV-2 infection triggers the de novo production of diverse, functional autoantibodies (AABs) that remain elevated in Long COVID (LC), but their pathogenic role remains unclear. Using tissue-based immunofluorescence, ELISA, human protein array, and mass spectrometry assays, we identified a broad range of AAB targets among individuals with LC. Individuals with neurocognitive symptoms showed increased AABs against central and peripheral nervous system proteins. Purified IgG reacted with human locus coeruleus, thalamus, adrenal gland, thyroid, and cross-reacted with mouse sciatic nerve and meninges. CNS-reactive AABs correlated with several neurological symptoms. MED20-targeting IgG from patients with LC showed enhanced antibody-dependent phagocytosis. Passive transfer of IgG from individuals with LC into mice induced fatigue-like behavior, loss of balance/coordination, thermal hyperalgesia, small fiber nerve damage, and increased pain-related neuronal activity, recapitulating patients’ symptoms. These findings suggest that targeting AABs might offer therapeutic benefits for this LC subgroup.

20 September 2024 in Science Immunology
Verified
Journal Article
Closed access
SBSachin H. Bhagchandani
Sachin H. Bhagchandani
LYLeerang Yang
Leerang Yang
JLJonathan H. Lam
Jonathan H. Lam
LMLaura Maiorino
Laura Maiorino
EBElana Ben-Akiva
Elana Ben-Akiva
DIDarrell J. Irvine
Darrell J. Irvine
Prolonging exposure to subunit vaccines during the primary immune response enhances humoral immunity. Escalating-dose immunization (EDI), administering vaccines every other day in an increasing pattern over 2 weeks, is particularly effective but challenging to implement clinically. Here, using an HIV Env trimer/saponin adjuvant vaccine, we explored simplified EDI regimens and found that a two-shot regimen administering 20% of the vaccine followed by the remaining 80% of the dose 7 days later increased T FH responses 6-fold, antigen-specific germinal center (GC) B cells 10-fold, and serum antibody titers 10-fold compared with bolus immunization. Computational modeling of T FH priming and the GC response suggested that enhanced activation/antigen loading on dendritic cells and increased capture of antigen delivered in the second dose by follicular dendritic cells contribute to these effects, predictions we verified experimentally. These results suggest that a two-shot priming approach can be used to substantially enhance responses to subunit vaccines.

28 January 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
Arnab RudraArnab Rudra
Arnab Rudra
JLJunwei Li
Junwei Li
RSRameen Shakur
Rameen Shakur
SBSachin Bhagchandani
Sachin Bhagchandani
RLRobert Langer
Robert Langer

31 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NJNitin Joshi
Nitin Joshi
JYJing Yan
Jing Yan
MDMickael Dang
Mickael Dang
KSKai Slaughter
Kai Slaughter
YWYufeng Wang
Yufeng Wang
JEJoerg Ermann
Joerg Ermann
Intra-articular delivery of disease-modifying osteoarthritis drugs (DMOADs) is likely to be most effective in the early stages of post-traumatic osteoarthritis (PTOA), when symptoms are minimal, and patients remain physically active. To ensure effective therapy, DMOAD delivery systems therefore must withstand repeated mechanical loading without altering the kinetics of drug release. While soft materials are typically preferred for DMOAD delivery, mechanical loading can compromise their structural integrity and disrupt controlled drug release. In this study, we present a mechanically resilient soft hydrogel that rapidly self-heals under conditions simulating human running while maintaining sustained release of the cathepsin-K inhibitor L-006235, used as a proof-of-concept DMOAD. This hydrogel demonstrated superior performance compared to a previously reported hydrogel designed for intra-articular drug delivery, which, in our study, neither recovered its structure nor maintained drug release under mechanical loading. When injected into mouse knee joints, the hydrogel provided consistent release kinetics of the encapsulated drug in both treadmill-running and nonrunning mice. In a mouse model of severe PTOA exacerbated by treadmill-running, the L-006235 hydrogel significantly reduced cartilage degeneration, whereas the free drug did not. Overall, our data underscore the hydrogel’s potential for treating PTOA in physically active patients.